ArticleDrug delivery and translational research2024
The promise of microneedle technologies for drug delivery.
Article in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 58 citations in OpenAlex.
- ROS-responsive tegafur-pheophorbide a conjugate-loaded microneedles for deep drug delivery and chemo-photodynamic therapy of superficial tumors.International journal of pharmaceutics: X · 2026Article
- Article
- Advanced in Co-Delivery, Controllable Therapy using Microneedle: From Design to Therapeutic Effects.Pharmaceutical research · 2026Review
- Microneedles combining delivery of hUMSC-derived exosomes and EGCG mitigate UV-induced skin damage.Journal of nanobiotechnology · 2025Article
- Polymeric microneedle advancements in macromolecule drug delivery: current trends, challenges, and future perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Review
- Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches.Bioactive materials · 2025Article
- Black phosphorus nanosheets encapsulated microneedle for multifunctional therapy for androgenic alopecia.Journal of nanobiotechnology · 2025Article
- A human skin-on-a-chip platform for microneedling-driven skin cancer treatment.Materials today. Bio · 2025Article
- Comparative study of permeation effects between vibrating microneedle and low-frequency sonophoresis systems.Drug delivery and translational research · 2024Article
- Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity.Pharmaceutics · 2024Review
- Drug delivery to and through the skin.Drug delivery and translational research · 2024Review
- Investigating Laser Ablation Process Parameters for the Fabrication of Customized Microneedle Arrays for Therapeutic Applications.Pharmaceutics · 2024Article
- Polymeric Microneedles Enhance Transdermal Delivery of Therapeutics.Pharmaceutics · 2024Article
- The Emerging Role of Silk Fibroin for the Development of Novel Drug Delivery Systems.Biomimetics (Basel, Switzerland) · 2024Review
- 3D Printing of Biodegradable Polymeric Microneedles for Transdermal Drug Delivery Applications.Pharmaceutics · 2024Article
- Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microneedle (MN) technologies offer the opportunity to improve patient access and target delivery of drugs and vaccines to specific tissues. When in the form of skin patches, MNs can be administered by personnel with minimal training, or could be self-administered by patients, which can improve access to medication, especially those usually requiring injection. Because MNs are small (usually sub-millimetre), they can be used for precise tissue targeting. MN patches have been extensively studied to administer vaccines and drugs in preclinical work as well as in multiple clinical trials. When formulated with biodegradable polymer, MNs can enable long-acting therapies by slowly releasing drug as the MNs biodegrade. Targeted drug delivery by hollow MNs has resulted in FDA-approved products that are able to inject vaccines to skin-resident immune cells to improve immune response and to target specific parts of the eye (e.g., suprachoroidal space) for increased efficacy and avoidance of side effects in other parts of the eye. Cosmetic products based on MN technologies are already in widespread use, mostly as anti-aging agents. With extensive research coupled with FDA-approved products, MN technology promises to continue is growth in research leading to products that can benefit patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.